Packaging - Dosage Forms & Services

Solubility is one of the key attributes of a drug candidate and one of the biggest challenges in drug development. Approximately 70-90% of New Molecular Entities (NMEs) in today’s drug pipeline are poorly soluble, which complicates delivery, resulting in poor bioavailability. The majority of these NMEs are...

Your Expert Partner for Oligonucleotide APIs - Process Development & Small-scale: scale-up to 10 mmol per run (small-scale equipment can also support early-stage supply) - Scale-up & Small to Medium-scale: scale-up to 100 mmol per run (supported by OligoPilotTM equipment) - Large-Scale Oligonucleotide Proc...

In addition to the largest worldwide capacity of commercial SPPS peptide production up to batch sizes exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 Metric Tons of Peptide, CordenPharma's multi-pronged approach to becoming the #1 peptide CDMO supplier extends to small-scale capabilities,...

As your CDMO partner, we provide development and manufacturing services for oral solid dose (OSD), non-sterile liquid and rectal dosage forms, and parenteral dosage forms for all phases of clinical development through commercialization. This broad spectrum of capabilities also allows formulations of highl...

CordenPharma’s Drug Product Innovation Centre of Excellence offers early phase formulation development and manufacturing services for Oral Solid Dose (OSD) drug products, including Bioavailability Enhancement technologies. In collaboration with our Solid State Centre of Excellence, we provide integrated AP...

Delivering the capabilities pharma needs to support its drug strategies, CordenPharma offers advanced LNP formulation technologies and forward-integrated sterile injectable manufacturing services to create a proven commercialization pathway. We support requirements for Pre-filled Syringes (PFS), Vials, Am...

Your Expert Partner for Peptide APIs
• >> Proven track record delivering world class manufacturing services from early stage to commercial supply, including complex products (e.g., Linaclotide, Enfuvirtide, Mifamurtide, Eptifibatide, Glatiramer, GLP analogues). • >> Proprietary...

Your Expert Partner for Oligonucleotide APIs

• Process Development & Small-scale: scale-up to 10 mmol per run(small-scale equipment can also support early-stage supply)

• Scale-up & Small to Medium-scale: scale-up to 100 mmol per run(supported by OligoPilotTM equipment)

• ...

Your Expert Partner for Standard & Proprietary Lipids & Carbohydrates
• >> A specialized Lipids offering including custom and standard lipids (Glycero-Phospholipids, Sphingolipids, Phosphocholine, Pegylated, and Cationic Lipids). • >> Lipids for support of mRNA vaccine ...

Your Expert Partner for Clinical & Commercial Injectable Drug Product Supply
• >> Wide & balanced range of injectable services incl. capability for combining injectable drugs and devices (combination products) • >> Aseptic and Terminal Sterilization Fill & Finish Technologies f...

One Source for Highly Potent & Oncological Products
• Integrated Supply: APIs & Oral / Sterile Drug Products • State-of-the-art facilities able to handle API and Drug Product of the highest potency • Development, clinical trial and commercial manufacturing • Full-service offering includi...

Full-Service Partner of Choice from Advanced Intermediates to Drug Products • Integrated network of cGMP facilities across Europe and US • 1,200 m3 of volumetric capacity in 20 L - 28,000 L reactors with various materials of construction • Clinical (Phase I-III) and ongoing commercial supply to multiple ...

After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary performance delivered by their expert team, CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers. The investment, which is still being finalized, will be fully operational in Q2 2024 and authorized by German authorities in H2 2024.

CordenPharma, a global CDMO leader in the manufacturing of Drug Substance (APIs) complex modalities (such as peptides, oligos and lipids) and injectable Drug Products, and GENEPEP, a French CRO specializing in the design, chemical synthesis, and optimization of peptides, peptide libraries and proteins, have celebrated one year of their fruitful collaboration.

CordenPharma, a global CDMO leader in the manufacture of Drug Substances (APIs) for complex modalities (such as peptides, GalNAc, lipids, etc.), Lipid NanoParticles (LNPs) containing xRNA / xDNA, and injectable Drug Products, and Certest, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with LNPs and API synthesis, have signed a partnership agreement.

Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produce 80 million vaccine doses within a short time, if needed. Following a successful expansion and qualification phase, the companies are now in a stand-by readiness phase for at least five years. Should the need arise, the German government will contact the developer of the specific mRNA vaccine required and WACKER & CordenPharma will then jointly produce this mRNA vaccine in line with the highest pharmaceutical quality standards.

Basel, Switzerland – 6 May 2025 > CordenPharma is proud to announce that the Science-Based Targets initiative (SBTi) has officially approved the group’s near-term greenhouse gas (GHG) emission reduction targets. Following a two-year carbon footprint measurement process resulting in a submission of the targets in November 2024, the SBTi’s Target Validation Team has confirmed that the group’s ambition is in conformance with the SBTi Standards and Guidance.

CordenPharma has submitted its near-term greenhouse gas (GHG) emission reduction targets to the Science Based Targets initiative (SBTi) for approval, marking a major step in its climate action commitments.
 

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. 

In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry.

Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics.

Peptide synthesis has traditionally relied on Classic Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), each with inherent limitations. LPPS, while efficient in reagent use, is only suitable for short peptides and requires tedious isolation steps. SPPS, widely adopted, is solvent-intensive and presents challenges in large-scale manufacturing. TAG-Assisted Peptide Synthesis (TAPS) combines the best of both worlds, offering an innovative hybrid approach that integrates LPPS and SPPS advantages. This method employs a TAG-anchor molecule, which solubilizes the growing peptide in an organic solution, allowing for multiple elongation cycles without isolation, significantly improving  efficiency. TAPS presents a highly efficient, sustainable, and scalable alternative to traditional peptide synthesis.